Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 95, Issue 1, Pages 98-109Publisher
WILEY
DOI: 10.1038/clpt.2013.155
Keywords
-
Categories
Ask authors/readers for more resources
Broadly speaking, the goals of the US Food and Drug Administration (FDA) special-designation programs-orphan, priority review, accelerated approval, and fast track-have been to expedite and sustain development and facilitate authorization of new medicines for unmet medical needs through so-called push-pull incentives. Although generally successful overtime, their success has been confined to certain therapeutic areas and, within those areas, certain diseases. Times have changed. The research and development (R&D) burdens and public health urgency that acted as an impetus for the FDA to intervene more actively for certain disease areas are now broadly experienced across many disease areas. This betokens the need for the FDA to make designation and implementation decisions with a view that reaches beyond the immediate horizons of political expediency and patient advocacy to encompass the broader expanse of factors that now influence R&D decisions-global competitiveness, the needs of investors, emerging sponsors, and patient-focused drug development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available